Anticancer activity of palladium-based complexes against triple-negative breast cancer

• Type: Another Publication in an International Scientific Journal
• Date: 2019

Authors

Vojtek, M (Author) Other; Marques, MPM (Author) Other; Ferreira, IMPLVO (Author) Other; Mota Filipe, H (Author) Other; Diniz, C (Author) FFUP

Journal

Title: Drug Discovery Today

Vol. 24

Pages: 1044-1058

ISSN: 1359-6446

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 2 Citations

Scopus - 36 Citations

Scientific classification

CORDIS: Health sciences

Other information

Authenticus ID: P-00Q-DZV

DOI: 10.1016/j.drudis.2019.02.012

Abstract (EN): Treatment of triple-negative breast carcinoma (TNBC) remains an unmet medical need with no targeted therapy available to date. Accounting for 10-30% of all human breast cancer tumors, this mammary carcinoma subtype has a particularly poor prognosis owing to its high metastatic potential, aggressive biology and limited pharmacological treatment options. Platinum chemotherapeutics are the mainstay therapy in patients with TNBC but their clinical use is limited by severe toxicity and acquired resistance. Palladium-based complexes are appealing alternative metal-based drugs because of significant similarities regarding structure and coordination chemistry with the platinum agents. This review summarizes the knowledge gathered so far on 121 Pd(II) complexes, emphasizing their anticancer activity and putative pharmacological targets toward TNBC.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 15